Pfizer plans to file for emergency-use authorisation from the FDA
- Vaccine shown to be 95% effective in final efficacy analysis of Phase 3 trial
- Plans to file for emergency-use authorisation within days
- No serious safety concerns observed in the tiral
- Side effects were mostly mild to moderate, cleared up quickly
- Only significant side effect greater than 2% frequency was fatigue at 3.7%
Risk trades are getting another shot in the arm on the news here, albeit a more modest one this time around. European stocks are holding slight gains now of around 0.4% while US futures are pushing slightly higher as well on the headlines.
The 95% efficacy rate bugs me a little, as this sort of reflects that this has turned into a huge vaccine race after Moderna announced a 94.5% efficacy rate earlier this week.
But if they have the data to back that up, then sure all the better for humanity.
